Jacobio Pharmaceuticals

Senesco Technologies is engaged in the research and development of genetic technologies to improve commercial agriculture and to treat major medical conditions in humans. Its platform technology is based on the identification and characterization of specific genes that are responsible for plant cell death and for programmed cell death in humans. The company is developing its technologies to address multiple opportunities within the global commercial agriculture industry, including extending the shelf life of perishable plant products, producing larger and leafier crops, increasing crop yields and reducing the harmful effects of environmental stresses, like drought. It is also researching applications of its technologies that may address the many human diseases associated with suppressed or premature apoptosis, including cancer, glaucoma and cardiovascular disease. Senesco has partnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, N.J.

Cubist Pharmaceuticals Inc is a biopharmaceutical company based in Lexington, MA, specializing in the development and commercialization of innovative therapies for serious and life-threatening conditions. With a focus on research and development, Cubist Pharmaceuticals Inc aims to address unmet medical needs and improve patient outcomes through cutting-edge science and strategic partnerships within the healthcare industry. Generated from their business information

Shire Specialty Pharmaceuticals is a division of Shire, which offers products under the VYVANSE, DAYTRANA, ADDERALL, FOSRENOL, AGRYLIN, ELAPRASE and PENTASA brand names for the treatment attention deficit hyperactivity disorder. The division sells its products to several pharmaceutical wholesale distributors and pharmacies in the United States and Europe. Founded in 1994, Shire is one of the leading specialty biopharmaceutical companies that focuses on meeting the needs of specialist physicians in Pennsylvania. The parent company has a staff of more than 1,600 employees. Shire s subsidiaries include Shire Human Genetic Therapies UK Limited, Shire Human Genetic Therapies Securities Corporation, Shire Investments & Finance (U.K.) Company, Shire Pharmaceutical Contracts Limited and Shire Intellectual Property 2 SRL.